Damien Mcdonald Sells 1,000 Shares of LivaNova PLC (NASDAQ:LIVN) Stock

LivaNova PLC (NASDAQ:LIVN) CEO Damien Mcdonald sold 1,000 shares of the stock in a transaction on Friday, November 1st. The stock was sold at an average price of $73.70, for a total value of $73,700.00.

Damien Mcdonald also recently made the following trade(s):

  • On Tuesday, October 1st, Damien Mcdonald sold 1,000 shares of LivaNova stock. The stock was sold at an average price of $73.82, for a total value of $73,820.00.
  • On Tuesday, September 3rd, Damien Mcdonald sold 1,000 shares of LivaNova stock. The stock was sold at an average price of $77.00, for a total value of $77,000.00.

LIVN opened at $73.93 on Thursday. The stock has a market cap of $3.44 billion, a PE ratio of 23.32, a P/E/G ratio of 3.24 and a beta of 0.53. The company has a quick ratio of 0.81, a current ratio of 1.17 and a debt-to-equity ratio of 0.21. LivaNova PLC has a 52 week low of $64.80 and a 52 week high of $126.99. The business’s fifty day simple moving average is $73.48 and its 200 day simple moving average is $74.25.

LivaNova (NASDAQ:LIVN) last released its earnings results on Wednesday, October 30th. The company reported $0.84 EPS for the quarter, beating the Zacks’ consensus estimate of $0.75 by $0.09. The business had revenue of $268.60 million for the quarter, compared to analysts’ expectations of $273.41 million. LivaNova had a positive return on equity of 9.44% and a negative net margin of 20.35%. The firm’s revenue was down 1.3% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.78 earnings per share. As a group, equities analysts anticipate that LivaNova PLC will post 2.69 earnings per share for the current year.

Several large investors have recently made changes to their positions in the company. Massachusetts Financial Services Co. MA grew its stake in shares of LivaNova by 12.6% during the third quarter. Massachusetts Financial Services Co. MA now owns 6,812 shares of the company’s stock valued at $503,000 after buying an additional 760 shares during the last quarter. Tower Research Capital LLC TRC grew its stake in shares of LivaNova by 60.0% during the third quarter. Tower Research Capital LLC TRC now owns 2,401 shares of the company’s stock valued at $177,000 after buying an additional 900 shares during the last quarter. Paradice Investment Management LLC grew its stake in shares of LivaNova by 720.1% during the third quarter. Paradice Investment Management LLC now owns 469,807 shares of the company’s stock valued at $34,667,000 after buying an additional 412,521 shares during the last quarter. Wedge Capital Management L L P NC grew its stake in shares of LivaNova by 1.2% during the third quarter. Wedge Capital Management L L P NC now owns 167,922 shares of the company’s stock valued at $12,391,000 after buying an additional 2,040 shares during the last quarter. Finally, Russell Investments Group Ltd. grew its stake in shares of LivaNova by 23.8% during the third quarter. Russell Investments Group Ltd. now owns 38,763 shares of the company’s stock valued at $2,860,000 after buying an additional 7,442 shares during the last quarter. 88.74% of the stock is currently owned by hedge funds and other institutional investors.

A number of brokerages recently issued reports on LIVN. Berenberg Bank reiterated a “buy” rating and issued a $114.00 price objective on shares of LivaNova in a research report on Monday, September 9th. BidaskClub downgraded LivaNova from a “strong-buy” rating to a “buy” rating in a research report on Saturday, August 24th. Piper Jaffray Companies set a $90.00 price objective on LivaNova and gave the stock a “buy” rating in a research report on Friday, September 6th. Zacks Investment Research downgraded LivaNova from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, October 2nd. Finally, ValuEngine upgraded LivaNova from a “hold” rating to a “buy” rating in a research report on Thursday. Three analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average price target of $97.67.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. It operates in two segments, Cardiovascular (CV”) and Neuromodulation (NM). The CV segment develops, produces, and sells cardiopulmonary products, including heart-lung machines, oxygenators, perfusion tubing sets, cannulae, and accessories, as well as related equipment and disposables for autotransfusion and autologous blood washing for neonatal, pediatric, and adult patients.

Further Reading: Diversification Important in Investing

Insider Buying and Selling by Quarter for LivaNova (NASDAQ:LIVN)

Receive News & Ratings for LivaNova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LivaNova and related companies with MarketBeat.com's FREE daily email newsletter.